WAMD
Clinical trials for WAMD explained in plain language.
Never miss a new study
Get alerted when new WAMD trials appear
Sign up with your email to follow new studies for WAMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye drug could cut injection frequency for wet AMD patients
Disease control OngoingThis phase 3 study tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 participants will receive either EYP-1901 or standard aflibercept injections. The goal is to see if EYP-1901 can maintain …
Matched conditions: WAMD
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 05:31 UTC
-
New eye implant could slash treatment shots for wet AMD
Disease control OngoingThis phase 3 study tests EYP-1901, a slow-release implant, against standard aflibercept injections in 400 people with wet AMD. The goal is to see if the implant can maintain or improve vision while reducing how often patients need eye injections over 2 years. Participants must ha…
Matched conditions: WAMD
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 05:30 UTC
-
One-Time gene therapy could free wet AMD patients from lifelong eye injections
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease and reduce the need for repeated eye injections. About 671 adults a…
Matched conditions: WAMD
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:41 UTC